SCHEDULE: Adverum Biotechnologies: BML Partners Cuts Stake to 9.7%

BML Investment Partners and Braden M. Leonard have reduced their beneficial ownership in Adverum Biotechnologies, Inc. to an aggregate of 9.7% after selling over 1 million shares.

Summary

• BML Investment Partners, L.P. and Braden M. Leonard (Reporting Persons) filed an Amendment No. 2 to Schedule 13D for Adverum Biotechnologies, Inc.
• The filing reports a decrease in beneficial ownership due to recent sales of Common Stock between December 1 and December 4, 2025.
• BML Investment Partners, L.P. now beneficially owns 1,958,080 shares, representing 8.9% of the class.
• Braden M. Leonard's aggregate beneficial ownership is 2,149,880 shares, representing 9.7% of the class. This includes 191,800 shares held directly and 1,958,080 shares held indirectly through BML Investment Partners, L.P.
• The percentage of class is calculated based on 22,077,467 shares of Common Stock outstanding on November 7, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 12, 2025.
• The shares were acquired in the ordinary course of business for investment purposes using working capital.

Sentiment

Score: 4

Explanation: The reduction in a significant investor's stake, particularly through sales, generally indicates a less favorable view of the investment, even if stated as 'ordinary course of business for investment purposes.' The potential for future discussions about strategic alternatives could be positive, but the immediate action is a divestment.

Negatives

• The reporting persons sold a total of 1,099,446 shares of Common Stock between December 1 and December 4, 2025.
• This reduction in stake by a significant investor could be perceived negatively by the market, potentially signaling a less favorable outlook on the investment.

Risks

• The reporting persons may evaluate their investment on a continuing basis and may, from time to time, acquire or dispose of Common Stock, which could introduce volatility to the stock price.
• Any future acquisitions or dispositions will depend on factors such as the price and availability of securities, the Issuer's business prospects, investment policies, and general market conditions.
• There is no certainty as to whether discussions with the Issuer regarding strategic alternatives or operational changes will occur or what their outcome might be.

Future Outlook

The reporting persons continuously evaluate their investment in Adverum Biotechnologies, Inc. and may, from time to time, acquire or dispose of Common Stock. They may also engage in discussions with the Issuer and its representatives and/or other stockholders, potentially exploring strategic alternatives or changes to the Issuer's operations, though there is no certainty regarding such discussions or their outcomes.

Industry Context

This filing reflects a significant investor's decision to reduce their stake in a biotechnology company. Such actions can be influenced by company-specific developments, broader sector trends, or portfolio rebalancing strategies within the highly dynamic and often volatile biotechnology industry.

Legal Proceedings

• None of the reporting persons (BML Investment Partners, L.P., BML Capital Management, LLC, or Braden M. Leonard) have been convicted in a criminal proceeding or a party to a civil proceeding related to federal or state securities laws in the past five years.

Stakeholder Impact

• Shareholders: May interpret the reduction in stake by a significant investor as a negative signal, potentially leading to downward pressure on the stock price.
• Management: May face increased scrutiny or pressure from the remaining significant shareholder (Braden M. Leonard) regarding strategic direction or operational changes.

Next Steps

• Reporting persons may continue to evaluate their investment in the Issuer.
• They may acquire or dispose of Common Stock based on various market and company-specific factors.
• They may engage in discussions with the Issuer and its representatives and/or other stockholders.
• They may seek to enter into a confidentiality agreement with the Issuer.
• They may discuss different strategic alternatives or changes to the Issuer's operations.

Key Dates

Recommendation

The filing indicates a significant reduction in beneficial ownership by BML Investment Partners, L.P. and Braden M. Leonard, who sold over 1 million shares of Adverum Biotechnologies, Inc. This action by a major investor typically signals a less favorable outlook on the stock, or at least a rebalancing of their portfolio. While the filing states the acquisitions were for investment purposes and future actions may include discussions on strategic alternatives, the immediate action of divestment suggests caution. Without further insight into the company's underlying fundamentals or the specific reasons for the divestment beyond 'ordinary course of business,' a 'hold' recommendation is prudent, advising investors to monitor future developments and the company's performance closely.

Keywords

Adverum Biotechnologies, BML Investment Partners, Braden M Leonard, Schedule 13D, Beneficial Ownership, Stock Sales, Biotechnology, Investment, Shareholder Update